
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Reuteri,Maltose,Sephadex
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Scioto Biosciences Announces Publication of Phase 1b Study in Autism
Details : SB-121 is a novel formulation of Lactobacillus reuteri (Lr) and was given to patients 15 to 45 years of age diagnosed with ASD. With the results now published, the study demonstrated that SB-121 was safe and well-tolerated.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
April 03, 2023
Lead Product(s) : Lactobacillus Reuteri,Maltose,Sephadex
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Reuteri,Maltose,Sephadex
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Top-line results from the study demonstrated that SB-121 (Lactobacillus Reuteri), represents the first clinical validation of ABT platform was safe and well tolerated.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Lactobacillus Reuteri,Maltose,Sephadex
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SB-121
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SB-121 is a Probiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Autistic Disorder.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : SB-121
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Genome & Company
Deal Size : $26.5 million
Deal Type : Series B Financing
Scioto Biosciences Receives Series B Investment from Genome & Company
Details : Funding will be used to support ongoing clinical development of Scioto’s lead product, SB-121, as a microbiome treatment for diseases affecting the gut-brain axis and gut injury.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Undisclosed
August 11, 2020
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Genome & Company
Deal Size : $26.5 million
Deal Type : Series B Financing
